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Common Cold Treatment Using Zinc
To the Editor The JAMA Clinical Evidence Synopsis on zinc for
the common cold by Drs Das and Singh1 was a summary of their
Cochrane review.2 I noticed inconsistencies in the synopsis and
so attempted to replicate their data.
In the Evidence Profile section of the synopsis, the au-
thors stated that the number of randomized clinical trials in-
cluded was “14 therapeutic (lozenges: low-dose = 5, high-
dose = 7, syrup = 2) … and 2 prophylactic …,” which implies that
the reported findings are purely based on randomized com-
parisons. However, their estimate of 3.43-day shorter colds for
high-dose vs low-dose zinc lozenge users appears not to be
based on a comparison of randomized groups but rather on an
arbitrary selection of 5 high-dose zinc groups from 7 trials com-
pared with 5 low-dose zinc groups from different trials.
There have not been 5 published randomized clinical trials
that directly compared high-dose and low-dose zinc lozenges.2,3
The pairing of the selected high-dose and low-dose zinc groups
also appeared arbitrary.
Furthermore, 3 of the 5 low-dose zinc trials had problems
in the formulation of their zinc lozenges so that zinc was not
released freely,3 and therefore, the low dosage of zinc was not
the only problem in the low-dose studies.
Das and Singh1 stated: “Zinc lozenges were associated with
a higher incidence of adverse events compared with placebo
(46.5% for lozenges vs 36.4% for placebo; number needed to
harm [NNH], 10).” This calculation was based on Analysis 2.12
of their Cochrane review.2
However, that analysis table counted the placebo group
from the study by Turner and Cetnarowski4 3 times. A meta-
analysis should not count the same randomized participants
more than once. The lower rate of adverse events in the pla-
cebo group may have been a statistical artifact caused by the
triple-counting of a single placebo group.
The negative findings for the low-dose zinc lozenge trials
may be caused by the low doses or problems in the lozenge for-
mulations. Therefore, the estimation of zinc lozenge effects
should focus on high-dose zinc lozenge studies. Three high-
dose zinc acetate lozenge trials found that colds were 42% (95%
CI, 35%-48%) shorter in the zinc groups.3
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In Reply The findings reported in the JAMA Clinical Evidence
Synopsis were based on randomized clinical trials, as was our
Cochrane review.1 The comparison of the 2 doses (≥75 mg/d vs
<75 mg/d) of zinc was performed as a part of a network meta-
analysis, which is a valid technique to assess the comparative
effectiveness of interventions among similar study popula-
tions that have not been compared directly in randomized clini-
cal trials.2
The prerequisite of a network meta-analysis is that the trials
should have used the same intervention in the same popula-
tion and setting, for the same health problem, and measured
the same outcome. We therefore selected trials using zinc loz-
enges that were conducted in the same country (United States),
in the same setting (outpatient setting), in the same popula-
tion (mostly adults), for the same health problem (naturally
acquired cold), and for the same outcome (duration of cold).
This analysis was not included in the Cochrane review.
We agree with Dr Hemilä’s point that 3 of the 5 low-dose
zinc trials had problems in the formulation of their zinc loz-
enges (were nonacetate lozenges) so that zinc was not
released freely. However, similar kinds of formulations that
released more and less ionic zinc were included in both low-
dose and high-dose groups.
There are many possible analytic approaches in a meta-
analysis, and we originally chose to triple count adverse event
data for 1 study.3 A more commonly used method is to com-
bine all relevant intervention groups into a single group, and
to combine all relevant control groups into a single control
group.4
We reanalyzed the data in this way and found a minimal
but insignificant difference from the previous calculation
(60.2% for lozenges vs 48.4% for placebo; number needed to
harm [NNH], 9). The conclusion remains the same: “zinc loz-
enges were associated with a higher incidence of adverse events
compared with placebo.” This is consistent with findings from
published clinical trials on zinc lozenges for the common cold.5
Moreover, regarding the study in question,3 the authors
reported adverse events to be more common in the lozenges
group (13%-19%; mean, 16%) than in the placebo group (10%).
We agree with Hemilä that the negative findings for the
low-dose (<75 mg/d) zinc lozenge trials may be related to the
low dose or problems in formulations, and the estimation of
zinc lozenge effects should focus on trials using high doses
(≥75 mg/d) of zinc.
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CORRECTION
Incorrect Dose in Figure: In the Original Contribution entitled “Effect of
Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic
Kidney Disease: The AMETHYST-DN Randomized Clinical Trial” published in the July
14, 2015, issue of JAMA,1 an incorrect study drug dose appeared in a figure. In
Figure 2, the starting patiromer dose reported as 16.2 in the x-axis for both stra-
tum 1 and stratum 2 in both the left and the right plots should have appeared as
16.8. This article was corrected online.
1. Bakris GL, Pitt B, Weir MR, et al; AMETHYST-DN Investigators. Effect of
patiromer on serum potassium level in patients with hyperkalemia and diabetic
kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):
151-161.
Wording Errors in the Text: In the Viewpoint entitled “Innovations of the Ameri-
cans With Disabilities Act: Confronting Disability Discrimination in Employment”
published in the June 9, 2015, issue of JAMA,1 the article should have stated more
clearly that the pre–Americans with Disabilities Act Amendments Act (ADAAA) re-
quirements for establishing coverage under the “regarded as” part of the defini-
tion are no longer required under the ADAAA. Under the ADAAA, an individual is
regarded as having a disability if he or she has been subject to discrimination “be-
cause of an actual or perceived physical or mental impairment whether or not the
impairment limits or is perceived to limit a major life activity.” This article was cor-
rected online.
1. Rothstein MA. Innovations of the Americans with Disabilities Act: confronting
disability discrimination in employment. JAMA. 2015;313(22):2221-2222.
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